Group 1 - The core viewpoint is that China's biopharmaceutical sector is experiencing significant growth in research and development capabilities, with a notable increase in the number of new drug approvals [1] - In 2023, the National Medical Products Administration (NMPA) approved 87 drugs, including 5 domestically innovative drugs, indicating a strengthening of China's drug development landscape [1] - The number of external licensing transactions has increased from 15 in 2019 to 33 in 2023, reflecting growing international confidence in Chinese biotechnology products [1] Group 2 - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the STAR Market, tracking an index of 30 representative high-quality companies [1] - Since the "924 market" period, the STAR Market innovative drug index has outperformed the Hang Seng Hong Kong Stock Connect innovative drug index, with respective gains of 117.04% and 109.62% during the market rebound from September 24, 2024, to September 30, 2025 [1] - The STAR Market innovative drug index may provide better exposure to the resilience of the STAR Market when market risk appetite increases [1]

医药板块延续反弹，科创创新药ETF国泰（589720）涨近2%。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创 新药指数，以高成长biotech为主，产品20%涨跌幅限制使其更贴合板块波动。 从业绩表现来看，去年"924行情"以来，科创新药指数跑赢主要港股创新药指数！2024年9月24日~2025 年8月31日市场反弹期间，科创新药/港股创新药/恒生港股通创新药指数涨幅分别为125.97%、 121.81%、116.32%，科创新药指数或有助于在市场风险偏好回升时更好地分享科创板的弹性。 注：市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及个股仅供参考，不构成股 票推荐，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相匹配的产 品。基金有风险，投资需谨慎。 （文章来源：每日经济新闻） ...